A dose-escalation study with the novel formulation of the oral pan-class I PI3K inhibitor BEZ235, solid dispersion system (SDS) sachet, in patients with advanced solid tumors.

被引：26

作者：

Peyton, J. D.

Ahnert, J. Rodon

Burris, H.

Britten, C.

Chen, L. C.

Tabernero, J.

Duval, V.

Rouyrre, N.

Silva, A. P.

Quadt, C.

Baselga, J.

机构：

[1] Sarah Cannon Res Inst, Nashville, TN USA

[2] Vall dHebron Univ Hosp, Barcelona, Spain

[3] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA

[4] Nevada Canc Inst, Las Vegas, NV USA

[5] Novartis Pharma AG, Basel, Switzerland

[6] Massachusetts Gen Hosp, Boston, MA 02114 USA

来源：

关键词：

D O I：

10.1200/jco.2011.29.15_suppl.3066

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

3066

引用

页数：1